Comparative Pharmacology
Head-to-head clinical analysis: CAROSPIR versus MIDAMOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAROSPIR versus MIDAMOR.
CAROSPIR vs MIDAMOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldosterone antagonist; competitively inhibits aldosterone binding to mineralocorticoid receptors in renal distal tubules, increasing sodium and water excretion while retaining potassium. Also has weak antagonistic activity at androgen receptors.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct, reducing sodium reabsorption and potassium excretion.
Spironolactone 25-100 mg orally once daily. Initial: 25 mg once daily; titrate at 4-week intervals based on response and potassium levels. Maximum: 100 mg/day.
5 mg orally once daily, increased to 10 mg if needed; maximum 20 mg/day.
None Documented
None Documented
Spironolactone has a short half-life of 1.3-2.0 hours, but its active metabolite canrenone has a prolonged half-life of 13-24 hours (mean 18 hours), leading to a sustained pharmacodynamic effect requiring 2-3 days to reach steady state.
Terminal half-life 6-9 hours; prolonged in renal impairment (up to 20 hours) and in heart failure
Approximately 50-60% of the dose is excreted in urine as active metabolites (primarily canrenone) and unchanged drug, with about 10-20% as unchanged spironolactone. Fecal excretion accounts for 20-30%, mainly as metabolites.
Renal: 80-90% as unchanged drug; biliary/fecal: <5%
Category C
Category C
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic